SCYNEXIS, Inc.

As of August 8, 2024, SCYNEXIS, Inc. is considered risky due to its overvaluation and negative financial metrics, including a low EV to EBITDA ratio of 0.13, underperformance compared to peers and the S&P 500, and a year-to-date return of -9.92%.

As of August 8, 2024, SCYNEXIS, Inc. is considered overvalued and risky due to negative financial metrics, including a -67.78% Return on Equity and a year-to-date stock decline of 39.67%, contrasting sharply with its peers like CytomX Therapeutics, Inc., which is rated attractive.

As of October 1, 2023, there is not enough technical data for SCYNEXIS, Inc. to determine if it is bullish or bearish.

As of March 2022, the management team of SCYNEXIS, Inc. includes Dr. Pamela Kirby (Chairman), Dr. Marco Taglietti (CEO), and directors Armando Anido, Laurent Arthaud, Steven Gilman, Ann Hanham, and David Hastings. They are responsible for the company's strategic direction and operations.

SCYNEXIS, Inc. is a micro-cap pharmaceutical company focused on the discovery and development of anti-infectives. As of March 2025, it reported net sales of $0 million and a net loss of $5 million, with a market cap of $29.27 million.

As of Jun 18, SCYNEXIS, Inc. has a market capitalization of 29.27 million and reported net sales of 2.64 million with a net profit of -27.09 million over the last four quarters.